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Abstract
Background: Several lines of evidence indicate that the central cannabinoid receptor 1 (CNR1)
as well as the major endocannabinoid degrading enzymes fatty acid amide hydrolase (FAAH), N-
acylethanolamine-hydrolyzing  acid amidase (NAAA) and monoglyceride lipase (MGLL) are
implicated in mediating the orexigenic effects of cannabinoids. The aim of this study was to analyse
whether nucleotide sequence variations in the CNR1, FAAH, NAAA and MGLL genes are associated
with anorexia nervosa (AN).
Methods: We analysed the association of a previously described (AAT)n repeat in the 3' flanking
region of CNR1 as well as a total of 15 single nucleotide polymorphisms (SNPs) representative of
regions with restricted haplotype diversity in CNR1, FAAH, NAAA or MGLL in up to 91 German AN
trios (patient with AN and both biological parents) using the transmission-disequilibrium-test
(TDT). One SNP was additionally analysed in an independent case-control study comprising 113
patients with AN and 178 normal weight controls. Genotyping was performed using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry, ARMS-PCR or using 3730xl
capillary sequencers.
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Results: The TDT revealed no evidence for association for any of the SNPs or the (AAT)n repeat
with AN (all two-sided uncorrected p-values > 0.05). The lowest p-value of 0.11 was detected for
the A-allele of the CNR1 SNP rs1049353 for which the transmission rate was 59% (95% confidence
interval 47%...70%). Further genotyping of rs1049353 in 113 additional independent patients with
AN and 178 normal weight controls could not substantiate the initial trend for association (p =
1.00).
Conclusion: As we found no evidence for an association of genetic variation in CNR1, FAAH, NAAA
and MGLL with AN, we conclude that genetic variations in these genes do not play a major role in
the etiology of AN in our study groups.
Background
Anorexia nervosa (AN) is an eating disorder with
unknown etiology. The multifactorial pathogenesis of AN
has been emphasized in various studies [1-3]. Accord-
ingly, heritability estimates derived from twin studies
revealed that 58–76% of the variance of AN can be
explained by genetic factors [4]. The highest incidence for
the development of AN is around puberty and patients
with AN are typically characterized by an abnormal eating
behaviour with disturbances of attitudes towards body
weight and shape [5]. Therefore, it is reasonable that
genetic factors regulating food intake and body weight are
implicated in the pathogenesis of AN [1,2,6,7].
One of the endogenous systems that, due to its therapeu-
tic potential in the treatment of obesity, recently reached
scientific interest is the endocannabinoid system. Both
exogenous (e.g. Δ9-tetrahydrocannabinol) and endog-
enous cannabinoids (e.g. anandamide and 2-arachido-
noylglycerol (2-AG)) stimulate food intake through
activation of the cannabinoid receptor 1 (CNR1) [8]. In
contrast, inhibition of CNR1 signalling through adminis-
tration of the selective inverse agonist rimonabant (Acom-
plia®) decreases food intake in both rodents [9-11] and
humans [12,13]. The endocannabinoid system further
interacts with the leptinergic system; obese rodents with
disturbed leptin signal transduction (ob/ob and db/db mice
as well as fa/fa rats) show elevated levels of anandamide
and 2-AG in the hypothalamus. Vice versa, leptin treat-
ment of ob/ob mice decreased hypothalamic levels of both,
anandamide and 2-AG [11]. Accordingly, compared to
age matched normal weight controls, serum levels of
anandamide are increased in patients with AN. Addition-
ally, plasma levels of leptin are negatively correlated with
anandamide in both, patients with AN and normal weight
healthy controls [2]. In light of these observations, it has
previously been suggested that the endocannabinoid sys-
tem might be implicated in the etiology of AN, in particu-
lar through its interaction with the leptinergic system
[2,7].
Hypoleptinemia is a cardinal feature of prolonged semi-
starvation that entails various metabolic and neuroendo-
crine alterations which are typically observed in patients
with acute AN [5,14] The most prominent neuroendo-
crine alterations mediated by semi-starvation induced
hypoleptinemia include amenorrhea, osteopenia/oste-
oporosis, and alterations of the hypothalamic-pituitary-
gonadal (HPG) and -adrenal (HPA) axis [5,14]. Addition-
ally, several lines of evidence indicate that hypoleptine-
mia entails development of hyperactivity in patients with
AN [5,14-18]. However, the implication of the endocan-
nabinoid system in body weight regulation together with
its interaction with the leptinergic system makes it a plau-
sible system implicated in the pathogenesis of AN [2,7].
The most prominent endocannabinoids are N-arachido-
noylethanolamine (anandamide) [19] and 2-arachido-
noylglycerol (2-AG) [20]. Both are synthesised through
cells on demand and undergo a rapid degradation
through specific hydrolases and lipases [8,21,22]. The
most prominent endocannabinoid degrading enzymes
are the fatty acid amide hydrolase (FAAH), the N-acyleth-
anolamine-hydrolyzing acid amidase (NAAA) and the
monoglyceride lipase (MGLL) [23]. FAAH is a membrane-
bound 60–65 kDa protein that is widely distributed
throughout the brain and the periphery [23,24]. Under
alkaline conditions, FAAH rapidly inhibits the orexigenic
effects of anandamide by degrading it to ethanolamine
and arachidonic acid [25,26]. NAAA is an enzyme with
similar function but has, in contrast to FAAH, its pH opti-
mum at 4.5–5 [27,28]. The monoglyceride lipase (MGLL)
is a serine hydrolase that hydrolyses 2-AG in glycerol and
arachidonic acid [22]. As endocannabinoids stimulate
food intake through activation of CNR1 and as FAAH,
NAAA and MGLL counteract the orexigenic effects of
endocannabinoids through their rapid degradation,
genetic variation of CNR1 leading to decreased receptor
signalling as well as genetic variation of FAAH, NAAA and
MGLL  leading to increased enzyme activity might be
implicated in the etiology of AN.
We performed association studies to analyse whether
allelic variation in CNR1,  FAAH,  NAAA  and  MGLL  is
related to the AN phenotype. We therefore genotyped the
previously described (AAT)n  repeat in the 3' flankingChild and Adolescent Psychiatry and Mental Health 2008, 2:33 http://www.capmh.com/content/2/1/33
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region of CNR1 as well as a total of 15 SNPs representative
of regions with restricted haplotype diversity in CNR1
(rs2180619, rs806379, rs1535255, rs2023239 and
rs1049353),  FAAH  (rs932816, rs324420, rs324419,
rs2295632 and rs873978), NAAA  (rs2292534,
rs6532046, rs10518142 and rs874546) and MGLL
(rs893294) in up to 91 German AN trios (patient with AN
and both biological parents). Genotyping was performed
using matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry or allele specific polymerase
chain reaction (ARMS-PCR). The AAT14 repeat allele of
CNR1 has recently been found to be associated with the
binge eating/purging type of AN whereby the AAT13 repeat
allele tended to be preferentially transmitted to patients
with the restricting type of AN [29]. Furthermore, SNP
rs324420 (c.385C/A) in the FAAH  gene, leading to
decreased enzyme activity and thus increased levels of
endocannabinoids and presumably increased food
intake, was recently found to be associated with obesity
[30] and drug abuse [31]. The CNR1 haplotype compris-
ing the minor alleles of SNP rs806379 (T-allele),
rs1535255 (G-allele) and rs2023239 (C-allele) has fur-
ther been shown to be associated with drug and alcohol
abuse in European and African Americans [32].
Methods
The ascertainment strategy was previously described in
detail [33]. Written informed consent was given by all par-
ticipants and in the case of minors, by their parents. The
study was approved by the ethics committees of the Uni-
versities of Marburg and Duisburg-Essen and carried out
according to the Declaration of Helsinki.
Study group 1 (AN trios) comprised 91 (3 male) patients
with AN (mean age 15.72 ± 2.04 years, mean BMI 15.42 ±
2.39 kg/m2) and both biological parents (mean age 46.73
± 5.67, mean BMI 26.22 ± 4.16 kg/m2).
Study group 2 (cases and controls) included 204 patients
with AN (113 patients with AN independent from study
group 1). The 113 (7 male) independent patients
included 65 (3 male) individuals with acute AN and 48 (4
male) individuals from a catamnestic study with a history
of AN. The acute patients had a mean age of 22.47 ± 11.67
years and a mean BMI of 14.81 ± 2.29 kg/m2. The catam-
nestic individuals had a mean age of 33.60 ± 7.22 years
and a mean BMI of 20.78 ± 2.05 kg/m2. In total, the 204
(10 male) patients had a mean age of 22.13 ± 10.03 years,
a mean BMI of 16.46 ± 3.30 kg/m2. The control group
comprised 178 healthy normal weight individuals with a
mean age of 24.58 ± 2.56 years and a mean BMI of 21.76
± 1.08 kg/m2. All patients with AN fulfilled the diagnostic
criteria for AN according to the diagnostic and statistical
manual of mental disorders (DSM-IV) [34].
Genotyping was performed using matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS, Sequenom, San Diego, CA). Only the
CNR1 SNP rs1049353 was genotyped using ARMS-PCR as
described previously [35]. The CNR1 (AAT) trinucleotide
repeat was genotyped using 3730xl capillary sequencers
(Applied Biosystems) and GeneMapper software (Version
4.0, Applied Biosystems). Primers for analyses of CNR1
variations were derived from genomic entry AL136096.7;
rs1049353 Fout: 5'-GGA CTC GGA CTG CCT GCA CAA A-
3'; Rout: 5'-AAA TTC TTT TCC TGT GCT GCC AGG G-3',
Fin: 5'-CAG AAA GCT GCA TCA AGA GCC CG-3', Rin: 5'-
GAC ATG GTT ACC TTG GCA ATC TTG CCT-3' (product
size outer primers: 175 bp, G-allele: 120 bp, A-allele: 105
bp); (AAT) trinucleotide repeat: F (FAM-labelled): 5'-CCT
TCT CCC AGC ACA ATC AT-3', R: 5'-TAC ATC TCG GTG
TGT GAT GTT CC A TGT TCC-3' (PCR-product size based
on genomic entry AL136096.7: 277 bp). SNP assays for
analyses with MALDI-TOF mass spectrometry were
designed with the SpectroDesigner software (Sequenom).
For validity of genotypes, alleles were rated independently
by at least two experienced individuals. Discrepancies
were resolved unambiguously either by reaching consen-
sus or by retyping.
The family-based association analyses were done applying
transmission disequilibrium tests (TDT) [36] while the
software FAMHAP (v16; http://www.uni-bonn.de/
~umte70e/becker.html) was used to investigate the haplo-
types consisting of the genotyped SNPs within the respec-
tive genes. Power considerations for the A-allele of
rs1049353 were performed using the program Quanto (v
1.2.3; http://hydra.usc.edu/gxe) at the one-sided signifi-
cance level of 0.05. Here, we assumed an AN prevalence of
0.5% and an allele frequency of 0.26 (accoding to http://
www.hapmap.org, CEU sample). Exact Cochran-Armitage
trend test, implemented in SAS, was applied to test for
association of the CNR1 SNP rs1049353 in case-control
data. If not indicated otherwise, all reported p-values are
two-sided and were not corrected for multiple testing as
none of the null hypotheses was rejected. A significance
level of α = 0.05 (two-sided) was applied.
Results
The Transmission-Disequilibrium Test (TDT) revealed no
indication for an association of the analysed SNPs or the
(AAT)n repeat with AN (Table 1). For the A-allele of the
CNR1 SNP rs1049353 the lowest p-value was 0.11 for an
estimated transmission rate of 59% (95% confidence
interval 47%...70%). Applying conditional logistic regres-
sion on the trio data, we obtained a multiplicative OR of
the A-allele at 1.43 (95% confidence interval 0.91...2.25).
Hence, in assuming a true effect of such size the power of
our consecutive case-control study comprising 113 addi-
tional independent patients with AN and 178 normalChild and Adolescent Psychiatry and Mental Health 2008, 2:33 http://www.capmh.com/content/2/1/33
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Table 1: Genotypes and TDT results of the analysed variants in CNR1. NAAA and MGLL in the AN trios
Gene SNP1,2 Alleles3 major/minor Location Exchange N4 Genotypes (%)5 Allele frequ.6 Transm. rate7 p-value8
A/A 26 (42.62) A: 0.64
A/G 26 (42.62)
CNR1 rs2180619 -22,959A/G Putative promoter 61 G/G 9 (14.75) G: 0.36 0.49 (G) 1.00
A/A 16 (26.23) A: 0.55
A/T 35 (57.38)
CNR1 rs806379 -6,274A/T Intron 2 61 T/T 10 (16.39) T: 0.45 0.52 (T) 0.90
T/T 43 (70.49) T: 0.84
T/G 16 (26.23)
CNR1 rs1535255 -6,215T/G Intron 2 61 G/G 2 (3.28) G: 0.16 0.50 (G) 1.00
T/T 43 (70.49) T: 0.84
T/C 16 (26.23)
CNR1 rs2023239 -5,489T/C Exon 3
Non-coding
61 C/C 2 (3.28) C: 0.16 0.50 (C) 1.00
G/G 38 (41.76) G: 0.65
G/A 43 (47.25)
CNR1 rs1049353 1,359G/A Exon 4
Thr453Thr
91 A/A 10 (10.99) A: 0.35 0.59 (A) 0.11
G/G 33 (54.10) G: 0.75
G/A 26 (42.62)
FAAH rs932816 -272G/A Putative
promoter
61 A/A 2 (3.28) A: 0.25 0.39 (A) 0.13
C/C 40 (66.67) C: 0.80
C/A 16 (26.67)
FAAH rs324420 10,741C/A Exon 3
Thr129Pro
60 A/A 4 (6.67) A: 0.20 0.56 (A) 0.61
G/G 49 (80.33) G: 0.89
G/A 11 (18.03)
FAAH rs324419 11,966G/A Exon 7
Cys299Cys
61 A/A 1 (1.64) A: 0.11 0.59 (A) 0.52
G/G 60 (98.36) G: 0.99
G/A 1 (1.64)
FAAH rs873978 13,883G/A Intron 7 61 A/A 0 (0.00) A: 0.01 1.00 (A) 1.00
C/C 34 (56.67) C: 0.73
C/A 20 (33.33)
FAAH rs2295632 19,542C/A 3'UTR 60 A/A 6 (10.0) A: 0.27 0.42 (A) 0.42
G/G 34 (56.67) G: 0.75
G/A 22 (36.67)
NAAA rs2292534 368A/G Intron 1 60 A/A 4 (6.67) A: 0.25 0.57 (A) 0.42
A/A 38 (62.30) A: 0.78
A/T 19 (31.15)
NAAA rs4859567 9,263A/T Intron 3 61 T/T 4 (6.56) T: 0.22 0.43 (T) 0.42
G/G 36 (60.00) G: 0.78
G/T 21 (35.00)
NAAA rs10518142 19,229G/T Intron 5 60 T/T 3 (5.00) T: 0.22 0.63 (T) 0.13
C/C 22 (36.07) C: 0.61Child and Adolescent Psychiatry and Mental Health 2008, 2:33 http://www.capmh.com/content/2/1/33
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weight controls would be about 60%. The initial finding,
however, could not be substantiated by the case-control
approach (exact p = 1.00). Similarly, a combined case-
control analysis including the 91 patients from the family-
trios (204 patients with AN and 178 controls) revealed no
association of the A-allele of rs1049353 with the AN phe-
notype (exact p = 0.27; multiplicative OR 1.20; 95% CI
0.88...1.65).
The  CNR1  haplotype comprising the minor alleles of
rs806379, rs1535255 and rs2023239 (TGC), previously
found to be associated with polysubstance abuse in Euro-
pean and African Americans [32], revealed likewise no
evidence for an association with AN in our study groups.
The allele frequencies of the CNR1  AAT trinucleotide
repeat were in accordance to previous results [29,37,38].
However, the AAT13 and AAT14 repeat alleles, previously
found to be preferentially transmitted to the restricting
and binge eating/purging type of AN, respectively, [29]
did not indicate evidence for an association with AN in
our samples (the global test for transmission disequilib-
rium indicated p = 0.35). Further haplotype analyses
resulted in lack of transmission disequilibrium for all
haplotypes, including those solely comprising frequently
transmitted alleles (p of global test for haplotypes of five
CNR1 SNPs: 0.66; five FAAH SNPs: 0.45 and four NAAA
SNPs: 0.72).
Discussion
We observed no evidence for a transmission disequilib-
rium for any of the 15 analysed SNPs in CNR1, FAAH,
NAAA or MGLL as assessed by the TDT. The strongest
effect with an estimated transmission rate of 59% hinting
at a preferential transmission of the CNR1 rs1049353 A-
allele to patients with AN was not substantiated in a sub-
sequent case-control study comprising 113 independent
patients with AN and 178 healthy controls. Also, combin-
ing the 113 independent patients with AN with the 91
patients from study group 1 did not alter this lack of evi-
dence for an association of the rs1049353 A-allele to
patients with AN. Contrary to our initial expectation of an
effect size of 1.43 estimated from the trio sample, the true
effect of this allele may be more moderate to be detected
by our, even pooled, relatively small case-control sample.
Even though the CNR1 SNP rs1049353 has not been ana-
lysed in patients with AN before, the G-allele of
rs1049353 was recently found to be associated with obes-
ity in a small case-control study comprising obese and
normal weight Italians [39]. However, several other stud-
ies could not confirm this finding [35,40,41]. The CNR1
TGC haplotype previously found to be associated with
polysubstance abuse in European and African Americans
[32] revealed likewise no evidence for a transmission dis-
equilibrium in our samples. Also the AAT14 and AAT13
repeat alleles of CNR1, which has previously been
reported to be preferentially transmitted in patients with
the binge eating/purging or restricting type of AN, respec-
tively, were not found to be preferentially transmitted to
patients with AN in our study. However, it has to be con-
sidered that the moderate to low sample size used in this
study might have contributed to the observed lack of asso-
ciation. Additionally, it can not be ruled out that other
variants, that are not in linkage disequilibrium with the
here analysed variants, might contribute to the pathogen-
esis of AN.
Exogenous and endogenous cannabinoids stimulate food
intake and promote weight gain in both, rodents [42] and
humans [12,13]. Oral application of Δ9-THC further
increases food intake and entails weight restoration in
cachectic patients receiving cancer chemotherapy [43,44].
Only one small trial comprising 11 (of which three
dropped out) patients with AN has focused on body
weight gain after treatment with Δ9-THC and found no
effect of oral application of Δ9-THC in doses up to 30 mg/
day on body weight gain after four weeks of treatment
[45]. However, in light of the small sample size, this
observation has to be regarded with caution, especially as
THC induced weight gain was compared to diazepam, for
which animal studies also indicate a stimulation of body
weight gain after its application [46,47].
Various association studies for AN have, with only limited
success, focused on genes implicated in the regulation of
food intake, as e.g. on the genes coding for leptin [48], the
leptin receptor (ObRb) [49], ghrelin [50,51], the brain
derived neurotrophic factor (BDNF) [52-55] or the tumor
necrosis factor-alpha (TNF-α) [56]. Most of the respective
C/T 31 (50.82)
NAAA rs6819442 22,995C/T Intron 9 61 T/T 8 (13.11) T: 0.39 0.56 (T) 0.42
T/T 36 (59.02) T: 0.75
T/A 19 (31.15)
MGLL rs893294 121,143T/A Intron 8 61 A/A 6 (9.84) A: 0.25 0.54 (A) 0.75
1 All SNPs were tested for Hardy-Weinberg equilibrium (exact p ≥ 0.05); 2 The TGC haplotype comprises the minor alleles of rs806379, rs1535255, 
and rs2023239; 3 Numbers are given according to genomic entry AL136096.7 and the translation start codon (nt+1 is the A of ATG); SNP alleles 
correspond to dbSNP http://www.ncbi.nlm.nih.gov/SNP/; 4 Number of anorexia nervosa trios genotyped; 5 Genotype frequencies in the patients 
with AN; 6 Allele frequencies in the patients with AN; 7 Transmission rate of the minor alleles; 8 for TDT
Table 1: Genotypes and TDT results of the analysed variants in CNR1. NAAA and MGLL in the AN trios (Continued)Child and Adolescent Psychiatry and Mental Health 2008, 2:33 http://www.capmh.com/content/2/1/33
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studies yielded negative results. However, Ribases et al.
(2003) reported strong association of the Val66Met poly-
morphism of BDNF with the restricting type of AN [52].
Additionally, this variant was associated with minimum
BMI in these patients [52]. Replication analyses of this
variant in 1,142 Caucasian patients with eating disorders
from five European countries confirmed the association of
this variant with all eating disorder subtypes including
AN, AN-restricting type, AN-binge-eating/purging type
and BN [53]. However, not all studies were able to con-
firm this finding [55].
Conclusion
In summary, we did not find evidence for an association
of the (AAT)n repeat and several SNPs in CNR1, FAAH,
NAAA and MGLL with AN in our samples. We thus con-
clude that the here analysed variations in CNR1, FAAH,
NAAA and MGLL at least do not seem to play a major role
in the genetic etiology of AN in our study groups.
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